✦ LIBER ✦

Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial

✍ Scribed by Haude, Michael; Erbel, Raimund; Erne, Paul; Verheye, Stefan; Degen, Hubertus; Böse, Dirk; Vermeersch, Paul; Wijnbergen, Inge; Weissman, Neil; Prati, Francesco; Waksman, Ron; Koolen, Jacques

Book ID: 120633570
Publisher: The Lancet
Year: 2013
Tongue: English
Weight: 854 KB
Volume: 381
Category: Article
ISSN: 0140-6736
DOI: 10.1016/S0140-6736(12)61765-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

TCT-32 First Report of the Four Year Cli

TCT-32 First Report of the Four Year Clinical Results of The ABSORB Trial Evaluating the Absorb Everolimus Eluting Bioresorbable Vascular Scaffold in the Treatment of Patients with de Novo Native Coronary Artery Lesions

✍ Chevalier, Bernard 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 54 KB

FIRST REPORT OF THE THREE YEAR CLINICAL

FIRST REPORT OF THE THREE YEAR CLINICAL AND MULTI–MODALITY IMAGING RESULTS OF THE ABSORB TRIAL EVALUATING THE ABSORB EVEROLIMUS ELUTING BIORESORBABLE VASCULAR SCAFFOLD IN THE TREATMENT OF PATIENTS WITH DE NOVO NATIVE CORONARY ARTERY LESIONS

✍ Serruys, Patrick 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 158 KB

TCT-37: ABSORB Cohort B Trial: 9 Months

TCT-37: ABSORB Cohort B Trial: 9 Months Clinical Results of the Evaluation of the Bioresorbable Everolimus-Eluting Vascular Scaffold (BVS) in the Treatment of Patients with de Novo Native Coronary Artery Lesions

📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 146 KB

TCT-181 Safety and Efficacy of a Novel A

TCT-181 Safety and Efficacy of a Novel Abluminal Groove-Filled Biodegradable Polymer Sirolimus-Eluting Stent for the Treatment of De Novo Coronary Lesions: 12-Month Results from the Prospectively Patient-Level Pooled Analysis of the TARGET I and TARGET II Trials

✍ Gao, Run-Lin; Xu, Bo; Lansky, Alexandra; Yang, Yuejin; Zhang, Ruiyan; Changsheng 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 72 KB

ABSORB II randomized controlled trial: A

ABSORB II randomized controlled trial: A clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: Rationale and study design

✍ Roberto Diletti; Patrick W. Serruys; Vasim Farooq; Krishnankutty Sudhir; Cecile 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 419 KB

Rationale and design of the dual antipla

Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions

✍ Laura Mauri; Dean J. Kereiakes; Sharon-Lise T. Normand; Stephen D. Wiviott; Davi 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 307 KB